What amount sold does Comera Life Sciences Holdings, Inc. report in Form D filings?

The latest linked filings report $7.5M sold across 4 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Comera Life Sciences Holdings, Inc.'s most recent SEC filing?

Comera Life Sciences Holdings, Inc.'s most recent Form D filing was on 2024-01-08.

How many investors does Comera Life Sciences Holdings, Inc. have?

The most recent Form D filing lists 12 investor(s).

Comera Life Sciences Holdings, Inc.

CIK: 0001907685·Biotechnology·WOBURN, MA

Reported Sold

$7,548,586

Total Filings

Identified Offerings

Last Filed

Jan 8, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jan 8, 2024Form D — New notice

Reported sold: $1,500,000 · Target: $1,500,000

Rule 506(b)·12 investors

Aug 7, 2023Form D — New notice

Reported sold: $2,249,000 · Target: $4,070,000

Rule 506(b)·12 investors

Aug 7, 2023Form D — New notice

Reported sold: $238,336 · Target: $238,336

Rule 506(b)·1 investor

Jan 12, 2023Form D — New notice

Reported sold: $3,561,250 · Target: $3,561,250

Rule 506(b)·14 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 4 identified offerings

$7,548,586

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Jeffrey S. Hackman

Executive Officer, Director

Appears on 4 filings

Michael Gerard Campbell

Executive Officer

Appears on 4 filings

Robert Patrick Mahoney

Executive Officer

Appears on 4 filings

James Sherblom

Director

Appears on 4 filings

Edward Aloysius Sullivan Jr.

Director

Appears on 4 filings

Sirshendu Roopom Banerjee

Director

Appears on 4 filings

Kirsten Flowers

Director

Appears on 4 filings

William A. Wexler

Director

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 8, 2024	New	$1,500,000	$1,500,000	12
Aug 7, 2023	New	$238,336	$238,336	1
Aug 7, 2023	New	$4,070,000	$2,249,000	12
Jan 12, 2023	New	$3,561,250	$3,561,250	14

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026